We are a development stage biopharmaceutical company focused primarily on the development of pharmaceuticals to safely address one of the major underlying causes of many chronic diseases – inflammation.
We believe we are well positioned for growth through the utilization of astaxanthin and zeaxanthin for chronic pharmaceutical applications by safely reducing chronic inflammation at the cellular and mitochondrial level – without inhibiting normal function.
CDX-101, our astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, our zeaxanthin pharmaceutical candidate, is being developed for macular degeneration, with a target initial indication of Stargardt disease.
We also have a commercial business unit that markets dietary supplements for inflammatory health. We recently launched our first commercial product, ZanthoSyn®, a safe anti-inflammatory for general health. ZanthoSyn® is a novel astaxanthin dietary supplement with superior absorption and purity, and is available through our commercial website, www.zanthosyn.com.
We believe that our pharmaceutical product candidates and our dietary supplements have competitive advantages primarily relating to a unique combination of the following benefits:
- An excellent safety profile that supports chronic use
- Broad anti-inflammatory activity and pleiotropic effects with potential application to several chronic diseases as pharmaceuticals and various areas of health as dietary supplements
- Oral dosing convenience
- Scalable manufacturing
- Economical pricing